Bioavailability of Phenytoin Sodium Capsules Available in Thailand Part II : In vivo Study

Journal of the Medical Association of Thailand

Volumn 81, Issue 1, 1998, Pages 63-69

  Suthisisang, Chuthamanee ^a   Payakachat, Nalin ^b   Chulavatnatol, Suvatna ^a   Towanabut, Somchai ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SILPAKORN UNIVERSITY   (Thailand)

^c PRASAT NEUROLOGICAL INSTITUTE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG MONITORING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HUMANS; MALE; PHENYTOIN; SINGLE-BLIND METHOD; THAILAND;

EID: 0031982621     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Julien RM, Halpern LH. Effects of diphenylhydantoin and other antiepileptic drugs on epileptiform activity and Purkinje cell discharge rates on epileptiform activity and Purkinje cell discharge rates. Epilepsia 1972; 13: 387-400.
2. Mclean MJ, Macdonald RL. Limitation of high frequency repetitive firing of cultured mouse neurons by anticonvulsant drugs. Neurology 1984; 34 (suppl 1): 228.
3. Delorenzo RL. Phenytoin : mechanisms of action. In : Lery Rit, Mattson RH, Meldrum BS, eds. Autiepileptic drugs, 4 th ed. New York : Raven Press 1995; 271-82.
4. Triman DM, Woodbury DM. Phenytoin: absorption, distribution, and excretion. Ibid: 301-14.
5. Browne TR, LeDuc B. Phenytoin: chemistry and biotransformation. Ibid: 283-300.
6. Nation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther 1994; 62: 41-55.
7. Jusko WJ. Bioavailability and disposition kinetics of phenytoin in man. In: Kellaway P, Petersen I, eds. Quantitative analytic studies in epilepsy. New York: Raven Press, 1976: 115-36.
8. Martin E, Tozer TN, Scheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm 1977; 5: 579-96.
9. Mikati M, Bassett N, Schachter S. Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Epilepsia 1992; 33: 359-65
10. Tsai J-J, Lai M-L, Yang Y-HK, Hung J-D. Comparison on bioequivalence of four phenytoin preparations in patients with multiple dose treatment. J Clin Pharmacol 1992; 32: 272-6.
11. Shah VP, Prasad Uk, Freeman C, Skelly JP, Cabana BE. Phenytoin II: in vitro-in vivo bioequivalence standard for 100-mg phenytoin sodium capsules. J Pharm Sci 1983; 72: 309-10.
12. Rosenbaum DH, Rowan AJ, Tuchman L, French JA. Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia 1994; 35: 655-60.
13. Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry 1992; 55: 688-91.
14. Meyer MC, Stranghn AB. Biopharmaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm 1993; 50: S17-S22.